Next Article in Journal
Small Prokaryotic DNA-Binding Proteins Protect Genome Integrity throughout the Life Cycle
Next Article in Special Issue
Special Issue: “G Protein-Coupled Receptor and Their Kinases in Cell Biology and Disease 2.0”
Previous Article in Journal
Sunitinib and Pterostilbene Combination Treatment Exerts Antitumor Effects in Gastric Cancer via Suppression of PDZD8
Previous Article in Special Issue
GPR18-Mediated Relaxation of Human Isolated Pulmonary Arteries
 
 
Review
Peer-Review Record

Sex Differences in Cardiovascular Diseases: A Matter of Estrogens, Ceramides, and Sphingosine 1-Phosphate

Int. J. Mol. Sci. 2022, 23(7), 4009; https://doi.org/10.3390/ijms23074009
by Beatrice Arosio 1, Graziamaria Corbi 2, Sergio Davinelli 2, Vienna Giordano 3, Daniela Liccardo 4, Antonio Rapacciuolo 5 and Alessandro Cannavo 3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(7), 4009; https://doi.org/10.3390/ijms23074009
Submission received: 23 March 2022 / Revised: 1 April 2022 / Accepted: 4 April 2022 / Published: 4 April 2022

Round 1

Reviewer 1 Report

Author has reported the most recent experimental and clinical observations about the role of Es and SLs' metabolism, emphasizing how these factors impact the CV system. However, dissecting the role of these molecules will provide the missing link  
between post-menopausal hypoestrogenism and increased CV risk;.optimizing both diagnostic and therapeutic strategies for treating CVDs selectively in men and women, and expanding the concept of "sex/gender CV medicine.  This work is interesting and highly citable. Although the article has scientific rigor, minor flows need to be corrected before publication. 

The author may add a recent references in the introduction section
Grammatical and typo errors are found
Provide some future paths of this study in conclusion.

Author Response

REVIEWER 1:

Author has reported the most recent experimental and clinical observations about the role of Es and SLs' metabolism, emphasizing how these factors impact the CV system. However, dissecting the role of these molecules will provide the missing link between post-menopausal hypoestrogenism and increased CV risk; optimizing both diagnostic and therapeutic strategies for treating CVDs selectively in men and women, and expanding the concept of "sex/gender CV medicine.  This work is interesting and highly citable. Although the article has scientific rigor, minor flows need to be corrected before publication.

Reply: We thank the Reviewer for His/Her constructive feedback and comments on our manuscript. We have revised the manuscript to address all the points raised. We trust that the responses and corresponding changes made to the revised manuscript, as detailed below, have satisfactorily addressed all the issues and that our revised manuscript will now be deemed suitable for publication in the International Journal of Molecular Sciences.

1) The author may add a recent references in the introduction section

Reply: We thank the Reviewer for raising this concern. As indicated, we updated the reference list. We added more recent references in the Introduction section to describe the implication of ERT in post-menopausal women (Gersh et al. Heart 2021 Prabakaran et al. Endocr Pract. 2022; Pan M et al.  Biosci Trends. 2022). Please see page 1, lines 42-44)

 2) Grammatical and typo errors are found:

 Reply: As indicated, we have revised our manuscript overall. Thanks

3) Provide some future paths of this study in conclusion:

Reply: This is another good point. We have included a discussion about future paths in the Conclusion section. Thanks.

Reviewer 2 Report

In my opinion, this is an important article in this field of research, summarizing current evidence on the role of sphingolipids and estrogens in dertiming sex-difference in cardiovascular health and disease. 

In general, the author discussed that sex-differences are mainly attributable to the effect of  estrogens and sphingolipids metabolism. I surely agree with this statement, even if from my point of view, most studies did not assess other factors affective cardiovascular health. For example, it has been widely demonstrated how behavioral risk factors for CVDs and metabolic disorders exhibit differences by gender (please consider for example DOI: 10.3389/fpubh.2020.00108; doi: 10.1177/2047487319834875). Moreover, it has been also demonstrated that some of these factors differentially act on male or female individual (please consider for example DOI: 10.1016/j.freeradbiomed.2018.12.018)

 For these reasons, I would suggest to include a section (or to add some text in an existing paragraph), discussing on these points. 

Minor points

Please double check the text for some typos 

Author Response

REVIEWER 2:

In my opinion, this is an important article in this field of research, summarizing current evidence on the role of sphingolipids and estrogens in determining sex-difference in cardiovascular health and disease.

Reply: We thank the Reviewer for His/Her constructive feedback and comments on our manuscript. We have revised the manuscript to address all the points raised. We trust that the responses and corresponding changes made to the revised manuscript, as detailed below, have satisfactorily addressed all the issues and that our revised manuscript will now be deemed suitable for publication in the International Journal of Molecular Sciences.

 1) In general, the author discussed that sex-differences are mainly attributable to the effect of estrogens and sphingolipids metabolism. I surely agree with this statement, even if from my point of view, most studies did not assess other factors affective cardiovascular health. For example, it has been widely demonstrated how behavioral risk factors for CVDs and metabolic disorders exhibit differences by gender (please consider for example DOI: 10.3389/fpubh.2020.00108; doi: 10.1177/2047487319834875). Moreover, it has been also demonstrated that some of these factors differentially act on male or female individual (please consider for example DOI: 10.1016/j.freeradbiomed.2018.12.018)

Reply: As indicated, we have included and discussed the mentioned above studies in the revised version of our manuscript. Please see the Conclusion section. Thanks

2) For these reasons, I would suggest to include a section (or to add some text in an existing paragraph), discussing on these points.

Reply: We thank you again for raising this important issue. As replied above, we have discussed these points in the Conclusion Section.

MINOR POINTS

1) Please double check the text for some typos

Reply: We have revised the manuscript accordingly. Thanks

Back to TopTop